Results 161 to 170 of about 183,897 (254)

HLA-E/peptide complexes differentially interact with NKG2A/CD94 and T cell receptors. [PDF]

open access: yesJ Immunol
Voogd L   +10 more
europepmc   +1 more source

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind   +7 more
wiley   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon   +11 more
wiley   +1 more source

Stratifying Multiple Sclerosis Susceptibility Risk: The Role of HLA-E*01 and Infectious Mononucleosis in a Population Cohort. [PDF]

open access: yesEur J Neurol
Nova A   +7 more
europepmc   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba   +2 more
wiley   +1 more source

Targeting the HLA-E-NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG. [PDF]

open access: yesJ Exp Clin Cancer Res
Deng Y   +15 more
europepmc   +1 more source

Locked in Transition: Examining the Role of Paradoxical Tensions in the Transition From Industrial Cluster to Eco‐Clusters

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Industrial clusters are central to the circular economy transition, yet how they develop into eco‐clusters and the paradoxical tensions this transformation fuels remain underexplored. Drawing on 48 in‐depth interviews and secondary data from a Turkish textile‐recycling cluster, we develop an empirically grounded model of eco‐cluster transition
Tulin Dzhengiz   +2 more
wiley   +1 more source

Synthetic Strategies for Activity‐Based Probes to Decode Ubiquitin‐Like Modifiers

open access: yesChemistry – A European Journal, EarlyView.
ABSTRACT Ubiquitin‐like proteins (Ubls) such as SUMO, NEDD8, ISG15, URM1, UFM1, FAT10, ATG8/ATG12, and FUBI are essential regulators of cellular homeostasis, controlling processes from protein stability and trafficking to immune signaling and autophagy.
Saibal Chanda   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy